VIVES Partners — 2020 Investments
1 investments dated 2020 · listed companies and verified rows first · show all
iTeos TherapeuticsMar 2020
Targets the tumor microenvironment to strengthen immune cell efficacy in eradicating cancer.
Cambridge, US
Michel Detheux(Executive Officer, Director)inDavid Hallal(Director)Priyanka Belawat(Director)CHris Buyse(Director)Jonathan Skipper(Director)
BoardDetlev Biniszkiewicz(Director)in
Co-investorsMPM BioImpact
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.